Phase I and Pharmacokinetic Study of Erlotinib for Solid Tumors in Patients With Hepatic or Renal Dysfunction: CALGB 60101
Antonius A. Miller(Roswell Park Comprehensive Cancer Center), Mark J. Ratain(University of Chicago), Kouros Owzar(Duke University), John L. Marshall(Vince Lombardi Cancer Clinic), Martin J. Edelman(Fox Chase Cancer Center), Donna Hollis(University of North Carolina at Chapel Hill), Lionel D. Lewis(Dartmouth College), Daryl J. Murry(University of Nebraska Medical Center), Hedy L. Kindler(University of Chicago), Raymond J. Hohl(Pennsylvania State University), Stuart M. Lichtman(Memorial Sloan Kettering Cancer Center), Miguel A. Villalona‐Calero(University of California, Irvine)
Cited by 68
Related Papers
Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2010|4.5k
Maintenance Olaparib for Germline <i>BRCA</i> -Mutated Metastatic Pancreatic Cancer
|New England Journal of Medicine|2019|2.2k
Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial
|The Lancet|2009|1.4k
Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma
|Nature|2011|1.3k
Lenalidomide after Stem-Cell Transplantation for Multiple Myeloma
|New England Journal of Medicine|2012|1.2k